Vaxart (STU:NB11) Treasury Stock : €-0.50 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Vaxart Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Vaxart's treasury stock for the quarter that ended in Mar. 2024 was €-0.50 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Vaxart Treasury Stock Historical Data

The historical data trend for Vaxart's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxart Treasury Stock Chart

Vaxart Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Treasury Stock

Get a 7-Day Free Trial

-0.34

Vaxart Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Treasury Stock	Get a 7-Day Free Trial															-0.01	-0.03	-0.04	-0.34	-0.50

Vaxart Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Vaxart (STU:NB11) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (STU:NB11) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

VXRT:USA VXRT:Mexico

Address

170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.vaxart.com

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Vaxart (STU:NB11) Headlines

No Headlines